tenacious in our search for transformative therapies
TARA-002
TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations (LMs). We are evaluating TARA-002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and LMs in the U.S., for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration.
IV CHOLINE CHLORIDE
An investigational phospholipid substrate replacement therapy for patients on parenteral support (PS). Approximately 80% of PS patients are choline deficient and have some degree of liver damage. IV Choline Chloride has the potential to become the first FDA approved IV choline formulation for PS patients.
